# South America Montelukast API Market > South America Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.84% - **2024:** $ 80.8 Million - **2025:** $ 83.09 Million - **2035:** $ 110 Million - **Key Players:** Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Aurobindo Pharma (IN), Cipla Ltd. (IN), Hikma Pharmaceuticals PLC (GB), Sandoz (CH), Zydus Cadila (IN) **Report ID:** MRFR/HC/51335-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-montelukast-api-market-53096 --- ## Market Summary ## **South America Montelukast API Market Overview** As per MRFR analysis, the South America Montelukast API Market Size was estimated at 90 (USD Million) in 2023. The South America Montelukast API Market Industry is expected to grow from 110 (USD Million) in 2024 to 350 (USD Million) by 2035. The South America Montelukast API Market CAGR (growth rate) is expected to be around 11.096% during the forecast period (2025 - 2035). ### **Key South America Montelukast API Market Trends Highlighted** The Montelukast API market in South America is experiencing substantial trends that are being driven by the increasing prevalence of respiratory diseases, such as allergic rhinitis and asthma. Montelukast, which is frequently prescribed for these conditions, is experiencing an increase in demand due to the availability of effective remedies and the growing awareness of asthma management among the general public. Additionally, the market is being bolstered by the implementation of initiatives by healthcare authorities in countries such as Brazil and Argentina to enhance asthma care by encouraging the use of essential medications. The Montelukast API market is further stimulated by the region's economic advancements and increasing disposable incomes, which also facilitate improved access to medications. Particularly through partnerships with pharmaceutical companies and local manufacturing, the Montelukast API market in South America remains brimming with opportunities. The potential for companies to invest in regional facilities and supply chains is expanding as a result of the emphasis on local production in several countries in South America as part of their healthcare policies. The development of innovative treatments can be facilitated by the exploration of collaborations with research institutions to improve drug formulations and delivery systems. The availability of generic Montelukast products has increased in recent years as patents expire, thereby enabling a broader segment of the population to access these essential medications. Furthermore, the proliferation of e-commerce platforms and online pharmacies in South America offers an alternative distribution channel, thereby facilitating patients' access to Montelukast products. The transition to digital solutions is transforming the way medications are supplied and ingested, resulting in a more well-informed patient population. In general, the South American Montelukast API market is poised for significant growth as a result of these dynamic market drivers and the changing behaviors of consumers. Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review ## **South America Montelukast API Market Drivers** ### **Rising Prevalence of Respiratory Disorders in South America** The increasing prevalence of respiratory disorders, particularly asthma and allergic rhinitis, is a significant driver of growth in the South America Montelukast API Market Industry. According to the Pan American Health Organization, it is estimated that around 15 million people in South America have asthma alone. With a population of over 430 million in this region, this equates to approximately 3.5% of the population. Additionally, the World Health Organization has indicated a concerning growth trend, with cases of asthma increasing by 12% over the last decade due to urbanization and pollution. ### **Government Initiatives to Enhance Respiratory Health** Government initiatives focused on respiratory health in South America are bolstering the **[Montelukast API Market](../../../reports/montelukast-api-market-7886)**. For instance, Brazil's Ministry of Health has launched various programs aimed at improving respiratory health, allocating substantial budgets for asthma education and management. In Brazil alone, recent government initiatives have invested over 200 million USD in awareness campaigns and treatment accessibility for asthma, increasing the population's awareness of effective treatments like Montelukast. Furthermore, these programs are likely to encourage pharmaceutical companies to invest more in Research and Development (R&D) related to Montelukast, thereby expanding the South America Montelukast API Market. ### **Increased Investment in Pharmaceutical Manufacturing** There is a marked increase in investment within the pharmaceutical manufacturing sector in South America, which directly benefits the Montelukast API Market. Recent reports from Brazil's National Association of Pharmaceutical Industries indicate that foreign direct investment in pharmaceutical manufacturing reached approximately 1.5 billion USD in the last year alone. Such investments improve manufacturing capabilities and increase the availability of APIs like Montelukast in regional markets. Established companies, including Novartis and Pfizer, are enhancing their production facilities, adapting to both domestic needs and export opportunities, which positively affects the South America Montelukast API Market landscape. ## **South America Montelukast API Market Segment Insights** ### **Montelukast API Market Application Insights** The South America Montelukast API Market, particularly in the Application segment, is witnessing notable growth driven by an increasing demand for effective treatment options for various respiratory and allergic conditions. Asthma is a major contributor to this market, as it affects a substantial percentage of the population, leading to a high level of awareness and treatment-seeking among patients. This respiratory ailment, characterized by inflamed airways, necessitates continued research and development of more effective medications to improve patients' quality of life. Allergic Rhinitis is also gaining significant attention within the South America Montelukast API Market, reflecting the rising prevalence of allergies due to environmental factors and lifestyle changes. As allergies become more common across diverse demographics, they create a considerable opportunity for the market through the development of targeted therapies. Bronchospasm represents another critical area where timely medical intervention is essential to manage symptoms and improve lung function for affected individuals. Urticaria, characterized by itchy hives and flare-ups, further adds to the complexity of allergic conditions that Montelukast addresses. Its management is vital, especially within urban populations exposed to various allergens. Lastly, the 'Others' segment highlights the diversity of conditions treated by Montelukast, representing additional avenues for growth in the market as awareness and prescription rates increase. Overall, the Application segment of the South America Montelukast API Market is not only significant due to its current value proposition but also critical in providing essential healthcare solutions to a growing number of patients in the region. As the industry evolves, it continues to focus on addressing the unmet needs of patients suffering from these common yet impactful conditions, ensuring a comprehensive approach towards respiratory and allergy management in South America. Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review ### **Montelukast API Market Regional Insights** The South America Montelukast API Market is seeing robust growth across its regional segments, with Brazil, Mexico, Argentina, and the Rest of South America playing pivotal roles in shaping the industry landscape. Brazil is one of the key players, commanding a significant portion of the market, driven by rising healthcare expenditures and an increasing prevalence of respiratory diseases. Mexico follows closely, benefiting from enhanced regulatory frameworks and improving access to healthcare services, thereby fostering the adoption of Montelukast. Argentina remains an important segment as well, characterized by a growing emphasis on chronic disease management and prevention strategies. Meanwhile, the Rest of South America is gaining traction with expanding pharmaceutical industries, which contribute to increased production and availability of Montelukast APIs. Collectively, these regions highlight various growth drivers, such as a rising awareness about asthma and allergies, and a greater push for innovation in the pharmaceutical sector. However, challenges, including market regulation and access disparities, may influence overall market dynamics. The diverse opportunities in South America ensure a promising outlook for the Montelukast API Market growth in the future, with potential for increased collaboration within the region's healthcare systems. Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review ## **South America Montelukast API Market Key Players and Competitive Insights** The South America Montelukast API Market is witnessing a dynamic landscape characterized by a variety of competitive forces, with multiple players working to capitalize on the rising demand for this crucial asthma and allergy medication. As awareness of respiratory diseases increases and healthcare infrastructure improves, companies in this region are focusing on innovation, production capabilities, and strategic collaborations. The market is shaped by factors including regulatory changes, supply chain advancements, and pricing strategies, which further define the competitive landscape. The ongoing efforts to expand market share and enhance product portfolios are evident as companies evaluate their positions and adapt to regional challenges while aiming for sustainability and patient-centric solutions. Teva Pharmaceutical Industries holds a strong presence in the South America Montelukast API Market, well-regarded for its extensive experience and product offerings. The company has established a solid reputation by delivering high-quality APIs with a focus on Montelukast. Their strength lies in their robust research and development capabilities, allowing them to innovate effectively while maintaining cost efficiencies. Teva's proactive approach to compliance with local regulations and its commitment to quality standards have further solidified its standing in the market. The company's distribution network and local partnerships enable it to reach a broad customer base, thereby reinforcing its competitive advantage in South America's increasingly demanding healthcare environment. Amgen has also carved out a significant niche within the South America Montelukast API Market, leveraging its pharmaceutical expertise and advanced biotechnological capabilities. With a key focus on specialized products and innovative therapies, Amgen has positioned itself as a formidable player. The company’s strengths include substantial investments in research and development and a focus on optimizing production operations to increase efficiency. Their commitment to creating impactful solutions for asthma and allergy patients significantly enhances their market presence. Amgen's strategic mergers and acquisitions in the region demonstrate its intent to expand its portfolio and strengthen its foothold in South America. This allows the company to remain competitive while catering to the evolving needs of healthcare providers and patients alike. ### **Key Companies in the South America Montelukast API Market Include** ### **South America Montelukast API Market Industry Developments** The South America Montelukast Active Pharmaceutical Ingredient (API) Market has recently witnessed several important developments. In October 2023, Teva Pharmaceutical Industries announced the expansion of its production capacity for Montelukast API to cater to growing demands across South America. Significant enhancements in the manufacturing process were also reported by Hetero Labs, aimed at improving efficiency and compliance with local regulatory standards. In terms of current affairs, the region's pharmaceutical landscape has been impacted by the recent partnerships formed between Sun Pharmaceutical Industries and local distributors, which aim to streamline supply chains for Montelukast. Over the past two years, companies like Novartis and Roche have focused on bolstering their market presence through increased Research and Development initiatives specific to the South American population’s healthcare needs, seeking to decrease asthma prevalence among children. Additionally, in August 2023, Dr. Reddy's Laboratories completed a strategic acquisition of a local firm specializing in respiratory treatments, which should facilitate broader access to Montelukast in the South America market. Overall, these developments suggest a growing awareness and focus on the importance of effective asthma therapies across the region. ### **South America Montelukast API Market Segmentation Insights** ### **Montelukast API Market Application Outlook** ### **Montelukast API Market Regional Outlook** ## Market Drivers ### Rising Healthcare Expenditure The montelukast api market is benefiting from the rising healthcare expenditure in South America. Governments and private sectors are increasingly investing in healthcare infrastructure, which includes the procurement of essential medications like montelukast. Reports indicate that healthcare spending in several South American countries has increased by over 5% annually, reflecting a commitment to improving health outcomes. This trend is likely to enhance the availability of montelukast in pharmacies and hospitals, thereby increasing its consumption. As healthcare systems evolve, the focus on preventive care and chronic disease management further supports the demand for effective treatments, positioning montelukast favorably in the market. ### Regulatory Changes Favoring Generic Drugs Recent regulatory changes in South America are favoring the montelukast api market, particularly concerning the approval and distribution of generic drugs. Authorities are streamlining the approval process for generics, which allows for quicker market entry and increased competition. This is crucial as montelukast faces patent expirations, leading to a surge in generic alternatives. The affordability of these generics is likely to attract a broader patient base, thereby expanding the market. Furthermore, regulatory support for quality assurance in generic manufacturing ensures that these products meet safety standards, which is essential for maintaining consumer confidence in the montelukast api market. ### Growing Awareness of Preventive Healthcare There is a notable shift towards preventive healthcare in South America, which is influencing the montelukast api market. As public health campaigns promote awareness about asthma and allergies, more individuals are seeking preventive treatments. Montelukast is recognized for its role in preventing asthma attacks, making it a preferred choice among healthcare providers. The increasing emphasis on early intervention and management of chronic conditions is likely to drive the demand for montelukast. Additionally, educational initiatives aimed at both healthcare professionals and patients are expected to enhance understanding of the medication's benefits, further propelling its market presence. ### Advancements in Pharmaceutical Manufacturing Technological advancements in pharmaceutical manufacturing processes are positively impacting the montelukast api market in South America. Enhanced production techniques, such as continuous manufacturing and process optimization, have led to increased efficiency and reduced costs. This is particularly relevant as the market sees a shift towards more affordable generic versions of montelukast. The ability to produce high-quality APIs at lower costs allows manufacturers to offer competitive pricing, which is crucial in a price-sensitive market. Furthermore, the adoption of stringent quality control measures ensures that the products meet regulatory standards, thereby enhancing consumer trust and driving market growth. ### Increasing Prevalence of Allergic Conditions The montelukast api market in South America is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. According to health reports, approximately 20% of the population in South America suffers from asthma, which is a significant driver for the demand for effective treatments. Montelukast, as a leukotriene receptor antagonist, is widely prescribed for managing these conditions. The increasing awareness among healthcare professionals and patients regarding the benefits of montelukast is likely to further boost its adoption. Additionally, the growing number of healthcare facilities and improved access to medications in urban areas contribute to the expansion of the montelukast api market. ## Future Outlook The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 2.84% CAGR from 2025 to 2035, driven by increasing respiratory disorders and rising healthcare investments. **New opportunities:** - Expansion of online distribution channels for montelukast APIs - Development of combination therapies to enhance efficacy - Investment in local manufacturing to reduce costs and improve supply chain efficiency By 2035, the montelukast API market is expected to achieve robust growth and increased market penetration. ## Segment Insights ### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing) In the South America montelukast api market, the application segment reveals Asthma as the largest contributor, capturing a significant share, while Allergic Rhinitis shows potential as the fastest-growing area within this segment. Other applications like Bronchospasm and Urticaria also play pivotal roles, but their market presence is comparatively smaller, indicating a distinct distribution among these therapeutic areas. The growth trends for this segment are driven by increasing incidences of respiratory diseases, heightened awareness of allergies, and advancements in treatment options. Asthma remains a predominant health concern, funded by both public and private sectors, thus ensuring robust growth. Meanwhile, the rise in awareness and diagnosis of Allergic Rhinitis is propelling its rapid growth, making it an emerging focus area for healthcare providers. Asthma: Dominant vs. Allergic Rhinitis: Emerging Asthma holds a dominant position in the application segment due to its extensive prevalence across various demographics. This chronic condition requires continuous management, which fuels steady demand for montelukast api. In contrast, Allergic Rhinitis is emerging rapidly as awareness increases regarding its impact on quality of life. With changing climatic conditions contributing to higher allergen prevalence, the market sees an upward trajectory in treatments for Allergic Rhinitis. The contrast between these two values highlights a clear division where Asthma maintains a significant market share while Allergic Rhinitis is catching up quickly, thanks to evolving healthcare strategies and patient needs. ## Regional Market Share Analysis ### Brazil : Robust Growth and Demand Trends Key markets include São Paulo, Rio de Janeiro, and Minas Gerais, where demand for montelukast is particularly high. The competitive landscape features major players like Merck & Co and Mylan N.V., alongside local manufacturers. The business environment is characterized by a mix of multinational and domestic firms, fostering innovation and competitive pricing. The pharmaceutical sector is increasingly focusing on respiratory therapies, making montelukast a vital component of treatment regimens. ### Mexico : Strategic Market Expansion Opportunities Key markets include Mexico City, Guadalajara, and Monterrey, where healthcare access is improving. The competitive landscape features players like Teva Pharmaceutical Industries and Aurobindo Pharma, which are expanding their presence. Local dynamics are influenced by a mix of public and private healthcare systems, creating opportunities for market entrants. The focus on respiratory health is driving innovation and product development in the sector. ### Argentina : Focus on Chronic Disease Management Key markets include Buenos Aires, Córdoba, and Mendoza, where healthcare facilities are expanding. The competitive landscape features significant players like Cipla Ltd. and Hikma Pharmaceuticals, which are well-positioned to capture market share. Local market dynamics are shaped by economic factors and healthcare policies, creating a favorable environment for growth. The focus on chronic disease management is driving demand for montelukast in various therapeutic applications. ### Rest of South America : Varied Growth Across Sub-regions Key markets include Chile, Colombia, and Peru, each with distinct competitive landscapes. Major players like Sandoz and Zydus Cadila are establishing a presence, but local firms also play a crucial role. The business environment is characterized by a mix of opportunities and challenges, with varying levels of healthcare access and affordability. The focus on respiratory health is becoming increasingly important, driving demand for montelukast across the region. ## Competitive Benchmarking The montelukast API market in South America is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include the rising prevalence of asthma and allergic rhinitis, alongside an increasing demand for cost-effective therapeutic options. Major players such as Merck & Co (US), Mylan N.V. (US), and Teva Pharmaceutical Industries Ltd. (IL) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Merck & Co (US) focuses on innovation through the development of new formulations, while Mylan N.V. (US) emphasizes regional expansion and partnerships to enhance market penetration. Teva Pharmaceutical Industries Ltd. (IL) appears to be concentrating on optimizing its supply chain to improve efficiency and reduce costs, collectively shaping a competitive environment that is increasingly reliant on strategic collaborations and technological advancements.In terms of business tactics, companies are localizing manufacturing to reduce costs and improve responsiveness to market demands. The market structure is moderately fragmented, with several players vying for market share, yet dominated by a few key companies that exert considerable influence. This fragmentation allows for niche players to emerge, but the collective strength of the major companies often dictates market trends and pricing strategies. In October Merck & Co (US) announced a partnership with a local South American pharmaceutical firm to enhance its distribution capabilities. This strategic move is likely to bolster Merck's presence in the region, allowing for more efficient delivery of its montelukast API products and potentially increasing market share. The partnership underscores the importance of local knowledge in navigating regulatory landscapes and consumer preferences. In September Mylan N.V. (US) launched a new generic version of montelukast in Brazil, aiming to capture a larger segment of the market. This initiative not only reflects Mylan's commitment to providing affordable healthcare solutions but also positions the company to compete more effectively against branded products. The introduction of generics is expected to drive down prices, benefiting consumers while intensifying competition among manufacturers. In August Teva Pharmaceutical Industries Ltd. (IL) expanded its production capacity in Argentina, a strategic decision aimed at meeting the growing demand for montelukast API in the region. This expansion is indicative of Teva's long-term commitment to the South American market and its recognition of the increasing need for respiratory medications. By enhancing production capabilities, Teva is likely to improve its supply chain reliability and responsiveness to market fluctuations. As of November current competitive trends in the montelukast API market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate to enhance innovation and efficiency. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative product offerings. This shift may redefine market dynamics, compelling companies to invest in R&D and sustainable practices to maintain a competitive edge. ## Recent News & Developments The South America Montelukast Active Pharmaceutical Ingredient (API) Market has recently witnessed several important developments. In October 2023, Teva Pharmaceutical Industries announced the expansion of its production capacity for Montelukast API to cater to growing demands across South America. Significant enhancements in the manufacturing process were also reported by Hetero Labs, aimed at improving efficiency and compliance with local regulatory standards. In terms of current affairs, the region's pharmaceutical landscape has been impacted by the recent partnerships formed between Sun Pharmaceutical Industries and local distributors, which aim to streamline supply chains for Montelukast. Over the past two years, companies like Novartis and Roche have focused on bolstering their market presence through increased Research and Development initiatives specific to the South American population’s healthcare needs, seeking to decrease asthma prevalence among children. Additionally, in August 2023, Dr. Reddy's Laboratories completed a strategic acquisition of a local firm specializing in respiratory treatments, which should facilitate broader access to Montelukast in the South America market. Overall, these developments suggest a growing awareness and focus on the importance of effective asthma therapies across the region. ## Report Scope | MARKET SIZE 2024 | 80.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 83.09(USD Million) | | MARKET SIZE 2035 | 110.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.84% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Merck & Co (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Aurobindo Pharma (IN), Cipla Ltd. (IN), Hikma Pharmaceuticals PLC (GB), Sandoz (CH), Zydus Cadila (IN) | | Segments Covered | Application | | Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. | | Key Market Dynamics | Rising demand for montelukast API driven by regulatory support and increasing respiratory disease prevalence in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the overall market valuation for montelukast API in 2024?** A: The overall market valuation for montelukast API was $80.8 Million in 2024. **Q: What is the projected market valuation for montelukast API by 2035?** A: The projected market valuation for montelukast API is $110.0 Million by 2035. **Q: What is the expected CAGR for the montelukast API market during the forecast period 2025 - 2035?** A: The expected CAGR for the montelukast API market during the forecast period 2025 - 2035 is 2.84%. **Q: Which companies are the key players in the montelukast API market?** A: Key players in the montelukast API market include Merck & Co, Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Cipla Ltd., Hikma Pharmaceuticals PLC, Sandoz, and Zydus Cadila. **Q: What application segment had the highest valuation in 2024 for montelukast API?** A: The asthma application segment had the highest valuation at $40.0 Million in 2024. **Q: How did the allergic rhinitis segment perform in 2024?** A: The allergic rhinitis segment performed with a valuation of $35.0 Million in 2024. **Q: What is the valuation range for the bronchospasm application segment in 2024?** A: The valuation range for the bronchospasm application segment in 2024 was between $15.0 Million and $20.0 Million. **Q: What is the expected growth trend for the montelukast API market in South America?** A: The montelukast API market in South America is expected to grow steadily, with a projected valuation increase to $110.0 Million by 2035. **Q: What was the valuation for the urticaria segment in 2024?** A: The valuation for the urticaria segment in 2024 was between $5.0 Million and $10.0 Million. **Q: What does the future hold for the 'others' application segment in the montelukast API market?** A: The 'others' application segment had a valuation of $5.8 Million in 2024, indicating potential for growth in the coming years. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-montelukast-api-market-53096*